Table 1.
Characteristics of studies included in review
| Study | Design | Patient population | Intervention | Comparator | Primary outcome(s) |
|---|---|---|---|---|---|
| John et al.,11 2010 | Prospective cohort | ESHF with UNOS status 1A or 1B, NYHA class IV listed for transplantation | LVAD support | Duration of support | 30-d and 1-yr mortality |
| Kumar et al.,17 2012 | Retrospective cohort | Patients with ESHF resulting from ICM or NICM who underwent LVAD implantation | LVAD support in patients with ICM | LVAD support in patients with NICM | 30-d and 1-yr mortality |
| Maltais et al.,18 2014 | Retrospective cohort | CABG + MVR surgery and end-stage ICM with severe mitral regurgitation | LVAD support | Conventional CABG + MVR surgery | 30-d and 1-yr mortality |
| Nishi et al.,20 2014 | Case series | ESHF eligible for cardiac transplantation | LVAD support | NA | 30-d mortality |
| Segura et al.,19 2015 | Case series | ESHF with LVAD implantation and history of anthracycline exposure | LVAD support | NA | Histopathological changes, mortality at follow-up |
| Tsiouris et al.,12 2013 | Retrospective cohort | Patients with ESHF resulting from ICM or NICM who underwent LVAD implantation | LVAD support in patients with ICM | LVAD support in patients with NICM | 30-d, 6-mo and 1-yr mortality |
| Yoshioka et al.,21 2014 | Case series | ESHF with LVAD implantation | LVAD support | NA | 1-, 2- and 3-yr mortality |
CABG = coronary artery bypass graft; ESHF = end-stage heart failure; ICM = ischemic cardiomyopathy; LVAD = left ventricular assist device; MVR = mitral valve replacement; NA = not applicable; NICM = nonischemic cardiomyopathy; NYHA = New York Heart Association; UNOS = United Network for Organ Sharing.